160 related articles for article (PubMed ID: 38765391)
1. The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates.
Goswami PR; Singh G; Patel T; Dave R
Cureus; 2024 Apr; 16(4):e58470. PubMed ID: 38765391
[TBL] [Abstract][Full Text] [Related]
2. What's new in the WHO 2022 classification of kidney tumours?
Alaghehbandan R; Siadat F; Trpkov K
Pathologica; 2022 Feb; 115(1):8-22. PubMed ID: 36645398
[TBL] [Abstract][Full Text] [Related]
3. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification.
Rizzo M; Caliò A; Brunelli M; Pezzicoli G; Ganini C; Martignoni G; Camillo P
Cancer Treat Rev; 2023 May; 116():102558. PubMed ID: 37060647
[TBL] [Abstract][Full Text] [Related]
5. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
Moch H; Amin MB; Berney DM; Compérat EM; Gill AJ; Hartmann A; Menon S; Raspollini MR; Rubin MA; Srigley JR; Hoon Tan P; Tickoo SK; Tsuzuki T; Turajlic S; Cree I; Netto GJ
Eur Urol; 2022 Nov; 82(5):458-468. PubMed ID: 35853783
[TBL] [Abstract][Full Text] [Related]
6. The New WHO Category of "Molecularly Defined Renal Carcinomas": Clinical and Diagnostic Features and Management Implications.
Kanakaraj J; Chang J; Hampton LJ; Smith SC
Urol Oncol; 2024 Jul; 42(7):211-219. PubMed ID: 38519377
[TBL] [Abstract][Full Text] [Related]
7. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma.
Lobo J; Ohashi R; Amin MB; Berney DM; Compérat EM; Cree IA; Gill AJ; Hartmann A; Menon S; Netto GJ; Raspollini MR; Rubin MA; Tan PH; Tickoo SK; Tsuzuki T; Turajlic S; Zhou M; Srigley JR; Moch H
Histopathology; 2022 Oct; 81(4):426-438. PubMed ID: 35596618
[TBL] [Abstract][Full Text] [Related]
8. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
[TBL] [Abstract][Full Text] [Related]
9. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
[TBL] [Abstract][Full Text] [Related]
10. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract][Full Text] [Related]
11. Update on Selected High-grade Renal Cell Carcinomas of the Kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.
Chen YB
Adv Anat Pathol; 2024 Mar; 31(2):118-125. PubMed ID: 38145398
[TBL] [Abstract][Full Text] [Related]
12. [2022 WHO classification of renal cell carcinomas: Focus on papillary renal cell carcinoma].
Bellal S; Kammerer-Jacquet SF; Rioux-Leclercq N;
Ann Pathol; 2024 May; ():. PubMed ID: 38729793
[TBL] [Abstract][Full Text] [Related]
13. New and emerging renal entities: a perspective post-WHO 2016 classification.
Trpkov K; Hes O
Histopathology; 2019 Jan; 74(1):31-59. PubMed ID: 30565301
[TBL] [Abstract][Full Text] [Related]
14. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
15. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges.
Mohanty SK; Lobo A; Cheng L
Hum Pathol; 2023 Jun; 136():123-143. PubMed ID: 36084769
[TBL] [Abstract][Full Text] [Related]
16. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations.
Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
[No Abstract] [Full Text] [Related]
17. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
Agaimy A; Hartmann A
Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
[TBL] [Abstract][Full Text] [Related]
18. [Provisional renal cell carcinoma subsets following the 2016 WHO classification].
Jenei A; Hes O; Kuthi L
Orv Hetil; 2020 Jan; 161(3):83-94. PubMed ID: 31928058
[TBL] [Abstract][Full Text] [Related]
19. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K; Hes O; Williamson SR; Adeniran AJ; Agaimy A; Alaghehbandan R; Amin MB; Argani P; Chen YB; Cheng L; Epstein JI; Cheville JC; Comperat E; da Cunha IW; Gordetsky JB; Gupta S; He H; Hirsch MS; Humphrey PA; Kapur P; Kojima F; Lopez JI; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Menon S; Netto GJ; Przybycin CG; Rao P; Rao Q; Reuter VE; Saleeb RM; Shah RB; Smith SC; Tickoo S; Tretiakova MS; True L; Verkarre V; Wobker SE; Zhou M; Gill AJ
Mod Pathol; 2021 Jul; 34(7):1392-1424. PubMed ID: 33664427
[TBL] [Abstract][Full Text] [Related]
20. Chromophobe renal cell carcinoma: current and controversial issues.
Moch H; Ohashi R
Pathology; 2021 Jan; 53(1):101-108. PubMed ID: 33183792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
